Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients

References

• Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Holmes TD, El-Sherbiny YM, Davison A, Clough SL, Blair GE, Cook GP. A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells. J Immunol 2011; 186:1538-45; PMID:21191066; http://dx.doi.org/10.4049/jimmunol.1000951
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27:5932-43; PMID:18836474; http://dx.doi.org/10.1038/onc.2008.267
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi.org/; http://dx.doi.org/10.1016/S0140-6736(00)03231-1
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA, Mayberry SD, Pequignot E, Brodsky I. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 1984; 44:370-4; PMID:6690050
   PubMed Web of Science ®Google Scholar
• Szkaradkiewicz A, Karpiński TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol 2010; 2010:901564-7; PMID:20445748; http://dx.doi.org/10.1155/2010/901564
   PubMedGoogle Scholar
• Mirjačić Martinović K, Konjević G, Babović N, Inić M. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. J Surg Res 2011; 171:637-49; PMID:20828749; http://dx.doi.org/10.1016/j.jss.2010.05.012
   PubMed Web of Science ®Google Scholar
• Konjević G, Jurisić V, Banićevic B, Spuzić I. The difference in NK-cell activity between patients with non-Hodgkin“s lymphomas and Hodgkin”s disease. Br J Haematol 1999; 104:144-51; PMID:10027727; http://dx.doi.org/10.1046/j.1365-2141.1999.01129.x
   PubMed Web of Science ®Google Scholar
• Verhoeven DHJ, de Hooge ASK, Mooiman ECK, Santos SJ, Dam ten MM, Gelderblom H, Melief CJM, Hogendoorn PCW, Egeler RM, van Tol MJD et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008; 45:3917-25; PMID:18657862; http://dx.doi.org/10.1016/j.molimm.2008.06.016
   PubMed Web of Science ®Google Scholar
• Viel S, Charrier E, Marçais A, Rouzaire P, Bienvenu J, Karlin L, Salles G, Walzer T. Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology 2013; 2:e26011; PMID:24327939; http://dx.doi.org/10.4161/onci.26011
   PubMed Web of Science ®Google Scholar
• Peng Y-P, Zhu Y, Zhang J-J, Xu Z-K, Qian Z-Y, Dai C-C, Jiang K-R, Wu J-L, Gao W-T, Li Q et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med 2013; 11:262; PMID:24138752; http://dx.doi.org/10.1186/1479-5876-11-262
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R, Tarazona R. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011; 60:1195-205; PMID:21644031; http://dx.doi.org/10.1007/s00262-011-1050-2
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73:3499-510; PMID:23592754; http://dx.doi.org/10.1158/0008-5472.CAN-13-0371
   PubMed Web of Science ®Google Scholar
• Schleypen JS, Geldern Von M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, Falk CS, Pohla H. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003; 106:905-12; PMID:12918068; http://dx.doi.org/10.1002/ijc.11321
   PubMed Web of Science ®Google Scholar
• Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N. Natural killer cells in non-hematopoietic malignancies. Front Immunol 2012; 3:395; PMID:23269924; http://dx.doi.org/10.3389/fimmu.2012.00395
   PubMed Web of Science ®Google Scholar
• Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353:701-11; PMID:16107623; http://dx.doi.org/10.1056/NEJMra041866
   PubMed Web of Science ®Google Scholar
• Casali PG, Blay J-Y, ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5):v198-203; PMID:20555081; http://dx.doi.org/10.1093/annonc/mdq209
   PubMed Web of Science ®Google Scholar
• Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels J-J, Blay J-Y, Coindre JM et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010; 21:2436-41; PMID:20439343; http://dx.doi.org/10.1093/annonc/mdq238
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem B-C, Abdel-Rahman S, Daugaard S, Salat C, Wendtner C-M et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11:561-70; PMID:20434400; http://dx.doi.org/10.1016/S1470-2045(10)70071-1
   PubMed Web of Science ®Google Scholar
• Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay J-Y, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011; 22:1266-72; PMID:21183581; http://dx.doi.org/10.1093/annonc/mdq608
   PubMed Web of Science ®Google Scholar
• Sinha S, Peach AHS. Diagnosis and management of soft tissue sarcoma. BMJ 2010; 341:c7170; PMID:21190968; http://dx.doi.org/10.1136/bmj.c7170
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13:459-63; PMID:11282985; http://dx.doi.org/10.1093/intimm/13.4.459
   PubMed Web of Science ®Google Scholar
• O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MWL et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012; 209:1869-82; PMID:22927549; http://dx.doi.org/10.1084/jem.20112738
   PubMed Web of Science ®Google Scholar
• Moser C, Schmidbauer C, Gürtler U, Gross C, Gehrmann M, Thonigs G, Pfister K, Multhoff G. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells. Cell Stress Chaperones 2002; 7:365-73; PMID:12653481; http://dx.doi.org/10.1379/1466-1268(2002)007<0365:IOTGIM>2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M, Hiddemann W. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones 2001; 6:337-44; PMID:11795470; http://dx.doi.org/10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 2005; 100:7-13; PMID:16109445; http://dx.doi.org/10.1016/j.imlet.2005.07.004
   PubMed Web of Science ®Google Scholar
• Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. Proc Natl Acad Sci USA 2007; 104:6329-34; PMID:17395718; http://dx.doi.org/10.1073/pnas.0611655104
   PubMed Web of Science ®Google Scholar
• Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Dueñas MG, Balderas-Peña LMA, Bravo-Cuellar A, Ortiz-Lazareno PC, Daneri-Navarro A. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009; 9:186; PMID:19531227; http://dx.doi.org/10.1186/1471-2407-9-186
   PubMed Web of Science ®Google Scholar
• Lee J-C, Lee K-M, Kim D-W, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172:7335-40; PMID:15187109; http://dx.doi.org/; http://dx.doi.org/10.4049/jimmunol.172.12.7335
   PubMed Web of Science ®Google Scholar
• Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril M-F et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 2013; 8:e76928; PMID:24204708; http://dx.doi.org/10.1371/journal.pone.0076928
   PubMedGoogle Scholar
• Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C, Nakakuma H, Spies T, Groh V. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 2010; 185:5732-42; PMID:20926796; http://dx.doi.org/10.4049/jimmunol.1002092
   PubMed Web of Science ®Google Scholar
• Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7:753-63; PMID:9430221; http://dx.doi.org/10.1016/S1074-7613(00)80394-5
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SEA, Yagita H, Takeda K, van Dommelen SLH, Degli-Esposti MA, Hayakawa Y. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42:501-10; PMID:15607806; http://dx.doi.org/10.1016/j.molimm.2004.07.034
   PubMed Web of Science ®Google Scholar
• Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010; 116:3865-74; PMID:20733159; http://dx.doi.org/10.1182/blood-2010-04-282301
   PubMed Web of Science ®Google Scholar
• Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukocyte Biol 2009; 85:88-97; PMID:18820174; http://dx.doi.org/10.1189/jlb.0208107
   PubMed Web of Science ®Google Scholar
• Nielsen CM, White MJ, Goodier MR, Riley EM. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol 2013; 4:422; PMID:24367364; http://dx.doi.org/10.3389/fimmu.2013.00422
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
   PubMed Web of Science ®Google Scholar
• Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R, Nelson PJ, Noessner E. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med 2011; 90:55-66; PMID:21870102; http://dx.doi.org/10.1007/s00109-011-0806-7
   PubMed Web of Science ®Google Scholar
• Geissler K, Fornara P, Lautenschläger C, Holzhausen H-J, Seliger B, Riemann D. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology 2015; 4:e985082; PMID:25949868; http://dx.doi.org/10.4161/2162402X.2014.985082
   PubMedGoogle Scholar
• Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M-C, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079-91; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847
   PubMed Web of Science ®Google Scholar
• Prinz PU, Mendler AN, Brech D, Masouris I, Oberneder R, Noessner E. NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention. Int J Cancer 2014; 135:1832-41; PMID:24615391; http://dx.doi.org/10.1002/ijc.28837
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G et al. Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816
   PubMed Web of Science ®Google Scholar
• Sanchez CJ, Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2010; 60:1-13; PMID:20697893; http://dx.doi.org/10.1007/s00262-010-0898-x
   PubMed Web of Science ®Google Scholar
• Iannone F, Porzia A, Peruzzi G, Birarelli P, Milana B, Sacco L, Dinatale G, Peparini N, Prezioso G, Battella S et al. Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function. Pancreas 2015; 44:386-93; PMID:25621568; http://dx.doi.org/10.1097/MPA.0000000000000288
   PubMed Web of Science ®Google Scholar
• Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12:718-25; PMID:16467081; http://dx.doi.org/10.1158/1078-0432.CCR-05-0857
   PubMed Web of Science ®Google Scholar
• Menard C, Blay J-Y, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF et al. Natural killer cell IFN- levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009; 69:3563-9; PMID:19351841; http://dx.doi.org/10.1158/0008-5472.CAN-08-3807
   PubMed Web of Science ®Google Scholar
• Ramirez MF, Ai D, Bauer M, Vauthey J-N, Gottumukkala V, Kee S, Shon D, Truty M, Kuerer HM, Kurz A et al. Innate immune function after breast, lung, and colorectal cancer surgery. J Surg Res 2015; 194:185-93; PMID:25475022; http://dx.doi.org/10.1016/j.jss.2014.10.030
   PubMed Web of Science ®Google Scholar
• Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 2013; 12:1069-78; PMID:23660515; http://dx.doi.org/10.1016/j.arr.2013.04.003
   PubMed Web of Science ®Google Scholar
• Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, Cecere F, Alma E, Zingoni A, Mainiero F et al. Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology 2015; 4:e990773; PMID:25949906; http://dx.doi.org/10.4161/2162402X.2014.990773
   PubMedGoogle Scholar
• Kikuchi Y, Oomori K, Kizawa I, Kato K. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma. Jpn J Clin Oncol 1985; 15:377-83; PMID:3839542
   PubMed Web of Science ®Google Scholar
• Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med 2015; 13:180; PMID:26040463; http://dx.doi.org/10.1186/s12967-015-0535-8
   PubMed Web of Science ®Google Scholar
• Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol 1996; 37:445-50; PMID:8599867; http://dx.doi.org/10.1007/s002800050410
   PubMed Web of Science ®Google Scholar
• Kiyohara T, Taniguchi K, Kubota S, Koga S, Sakuragi T, Saitoh Y. Induction of lymphokine-activated killer-like cells by cancer chemotherapy. J Exp Med 1988; 168:2355-60; PMID:3199072; http://dx.doi.org/10.1084/jem.168.6.2355
   PubMed Web of Science ®Google Scholar
• Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, Eksborg S, Klein E, Skribek H, Szekely L. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007; 6:644-54; PMID:17308061; http://dx.doi.org/10.1158/1535-7163.MCT-06-0358
   PubMed Web of Science ®Google Scholar
• Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 2016; 18:10; PMID:26810608; http://dx.doi.org/10.1186/s13058-015-0669-x
   PubMed Web of Science ®Google Scholar
• Eissens DN, Schaap NPM, Preijers FWMB, Dolstra H, van Cranenbroek B, Schattenberg AVM, Joosten I, van der Meer A. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia 2010; 24:583-91; PMID:20033055; http://dx.doi.org/10.1038/leu.2009.269
   PubMed Web of Science ®Google Scholar
• Vinzenz K, Micksche M. Systemic and regional natural cytotoxicity in patients with head and neck cancer. J Maxillofac Surg 1986; 14:270-5; PMID:3464682; http://dx.doi.org/10.1016/S0301-0503(86)80303-4
   PubMed Web of Science ®Google Scholar
• Ferrari de Andrade L, Ngiow SF, Stannard K, Rusakiewicz S, Kalimutho M, Khanna KK, Tey S-K, Takeda K, Zitvogel L, Martinet L et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res 2014; 74:7298-308; PMID:25351955; http://dx.doi.org/10.1158/0008-5472.CAN-14-1339
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40; PMID:11698225; http://dx.doi.org/10.1016/S1471-4906(01)02060-9
   PubMed Web of Science ®Google Scholar
• Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107:159-66; PMID:16150947; http://dx.doi.org/10.1182/blood-2005-04-1351
   PubMed Web of Science ®Google Scholar
• Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer 2014; 13:34; PMID:24565056; http://dx.doi.org/10.1186/1476-4598-13-34
   PubMed Web of Science ®Google Scholar
• Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, Allard M, Bercovici N, Avril M-F, Caignard A. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 2011; 17:2628-37; PMID:21224372; http://dx.doi.org/10.1158/1078-0432.CCR-10-2084
   PubMed Web of Science ®Google Scholar
• Kiaii S, Choudhury A, Mozaffari F, Rezvany R, Lundin J, Mellstedt H, Osterborg A. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leuk Lymphoma 2006; 47:1229-38; PMID:16923551; http://dx.doi.org/10.1080/10428190600565503
   PubMed Web of Science ®Google Scholar
• Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006; 239:22-30; PMID:16630603; http://dx.doi.org/10.1016/j.cellimm.2006.03.002
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6:558-68; PMID:15548365; http://dx.doi.org/10.1593/neo.04316
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.1158/1078-0432.CCR-11-1347
   PubMed Web of Science ®Google Scholar
• Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, Miller JS. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp Hematol 2000; 28:96-103; PMID:10658681; http://dx.doi.org/10.1016/S0301-472X(99)00129-0
   PubMed Web of Science ®Google Scholar
• Escudier B, Farace F, Angevin E, Charpentier F, Nitenberg G, Triebel F, Hercend T. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 1994; 30A:1078-83; PMID:7654433; http://dx.doi.org/10.1016/0959-8049(94)90460-X
   PubMed Web of Science ®Google Scholar
• Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995; 1:607-14; PMID:9816022
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24:1861-71; PMID:15274367
   PubMed Web of Science ®Google Scholar
• Macdonald HR, Engers HD, Cerottini JC, Brunner KT. Generation of cytotoxic T lymphocytes in vitro. II. Effect of repeated exposure to alloantigens on the cytotoxic activity of long-term mixed leukocyte cultures. J Exp Med 1974; 140:718-30; PMID:4278109; http://dx.doi.org/10.1084/jem.140.3.718
   PubMed Web of Science ®Google Scholar
• Prinz PU, Mendler AN, Masouris I, Durner L, Oberneder R, Noessner E. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention. J Immunol 2012; 188:5990-6000; PMID:22573804; http://dx.doi.org/10.4049/jimmunol.1103028
   PubMed Web of Science ®Google Scholar